Balancing the risks and benefits of concurrent reirradiation and chemotherapy for recurrent head and neck cancers is difficult for physicians at even the most experienced centers. Research recently published in Cancer, however, suggests that selection of patients who may benefit from this therapy should be based on the patient’s previous treatment and the amount of time that has elapsed since initial treatment…
Dr. Johnson gave the presentation at COSM 2011.
Chemoradiation therapy (CRT) for head and neck cancer is overused at some centers in patients with early-stage laryngeal cancer, and more care should be taken not to overtreat patients with therapy that can have toxic effects, said invited lecturer Jonas Johnson, MD, at the Annual Meeting of the Triological Society, held here on April 29 as part of the Combined Otolaryngology Spring Meetings.
Quantitative real-time polymerase chain reaction (Q-PCR) can be a valuable tool in the operating room to determine whether head and neck cancer patients should go on to elective neck dissection, researchers said here on April 29 at the Annual Meeting of the Triological Society, held as part of the Combined Otolaryngology Spring Meetings.
What are the patient variables associated with swallowing dysfunction in head and neck cancer (HNCa) patients prior to intervention? Background: Recent studies have shown that pretreatment deficits are common in HNCa […]
When performing certain procedures, many otolaryngologists use succinylcholine, a neuromuscular blocking agent, to help them monitor the facial nerve.
Which treatment for Tis/T1 glottic carcinoma among adult patients, transoral CO2 laser excision (TOL) or external beam radiation (XRT), is superior in terms of cost utility? Background: Cancer of the larynx […]
Patients with cancer of the larynx who are treated at teaching and research hospitals that see high volumes of such patients are the least likely to die within a year of their diagnoses, researchers said at the annual meeting of the American Head and Neck Society.
Mounting evidence suggests that human papillomavirus (HPV)-positive oropharyngeal cancer has an improved prognosis compared with HPV-negative disease. The most recent supportive evidence comes from an analysis of a Phase III trial presented at the 2009 annual meeting of the American Society of Clinical Oncology.
What needs to be in the follow-up of certain patients who have undergone treatment for thyroid cancer? Uncertainties still exist, but change is in the air. The 2009 American Thyroid Association (ATA) guidelines promise to clarify at least some issues that affect practice.